These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 24391388)

  • 1. Overview of omega-3 Fatty Acid therapies.
    Bradberry JC; Hilleman DE
    P T; 2013 Nov; 38(11):681-91. PubMed ID: 24391388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
    Brinton EA; Mason RP
    Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS
    Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.
    Tajuddin N; Shaikh A; Hassan A
    Diabetes Metab Syndr Obes; 2016; 9():109-18. PubMed ID: 27143943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J; Anzalone D; Hilleman D; Catini J
    Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icosapent ethyl for the treatment of hypertriglyceridemia.
    Ballantyne CM; Braeckman RA; Soni PN
    Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl.
    Hassan A; Tajuddin N; Shaikh A
    Cardiol Ther; 2015 Jun; 4(1):83-93. PubMed ID: 25515964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
    Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
    Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
    Ito MK
    P T; 2015 Dec; 40(12):826-57. PubMed ID: 26681905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
    Crandell JR
    Clin Med Insights Cardiol; 2016; 10():123-8. PubMed ID: 27478390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
    Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
    Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.
    Sharp RP; Gales BJ; Sirajuddin R
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):83-92. PubMed ID: 29080985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable.
    Hilleman D; Smer A
    Manag Care; 2016 Jan; 25(1):46-52. PubMed ID: 26882630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.